Volume 111, Issue 6, Pages 1105–1106
Steven R. Lindheim, M.D., M.M.M.a, Jody Lynee Madeira, J.D., Ph.D.b, Bala Bagavath, M.D.c, John C. Petrozza, M.D.d
Over the past several years, the commercial status of the Essure Coil, a permanent hysteroscopic sterilization device, has switched from assured to pressured. In July 2018, the device's manufacturer, Bayer Healthcare, announced that it would halt sales in the United States (the last country in which the device has been offered) by year's end. This decision was prompted by years of declining sales revenue and came after thousands of women filed complaints of adverse events, including device expulsion, uterine and tubal perforation, intractable pelvic pain, and bleeding necessitating hysterectomy, device-related death, unintended pregnancy and miscarriage, and a variety of other chronic symptoms (1).